DigeHealth raises CHF 1.25 million to advance continuous gastrointestinal monitoring

DigeHealth has raised CHF 1.25 million to accelerate the development of a wearable device that continuously monitors gastrointestinal activity using acoustics and artificial intelligence.

Vaud-based medtech start-up DigeHealth has secured CHF 1.25 million in seed financing to accelerate the development of its wearable technology designed to continuously monitor gastrointestinal function. Based at the Biopôle life sciences campus in Epalinges, the company aims to transform how digestive disorders are detected, monitored and managed in both hospital and home-care settings.

The funding round was led by Medin Fund Management, with participation from the Lichtsteiner Foundation, Digital Africa and Joylab SA. The capital will be used to advance product development, clinical validation and regulatory approval, supporting DigeHealth’s ambition to bring a new generation of digital biomarkers into gastroenterology.

Founded in 2023, DigeHealth is developing a non-invasive wearable device that captures and analyzes bowel sounds using advanced acoustics, sensor fusion and artificial intelligence. By “listening to the gut,” the system enables continuous monitoring of intestinal activity, an area that remains difficult to assess with existing diagnostic tools. According to the company, gastrointestinal disorders affect around 20 percent of the global population, yet clinicians still lack efficient solutions for long-term, real-world monitoring of disease progression and treatment response.

Transforming bowel sounds into objective, actionable digital biomarkers

DigeHealth is an EPFL start-up and a spin-off of Swiss health innovation company Evoleen. Its technology is designed to support a wide range of clinical use cases, from post-operative ileus and nutritional intolerance to chronic conditions such as inflammatory bowel disease and neurogenic bowel dysfunction. By transforming bowel sounds into objective, actionable digital biomarkers, the company aims to improve clinical decision-making and personalize patient care.

“We want to make gut health continuously measurable and clinically actionable,” said Nour Ghalia Abassi, Co-Founder and CEO of DigeHealth. The seed financing will also enable the company to strengthen its AI capabilities and expand access to clinical data as it prepares for broader clinical deployment.

The investment highlights growing interest in digital health solutions emerging from Western Switzerland’s life sciences ecosystem. From its central location at the Biopôle, DigeHealth benefits from close proximity to research institutions, hospitals and innovation partners, reinforcing the region’s position as a hub for medical technology, digital health and translational research.